Moomaw Scott sold $682K of LQDA

Moomaw Scott (Chief Commercial Officer) sold 9,539 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.68M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moomaw Scott
Published Jul 15, 2026, 12:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

Because the sale is pre-arranged under a 10b5-1 plan and lacks any accompanying corporate update, it is unlikely to change the investment thesis on its own.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental information to drive repricing.

03

What to watch

The article provides sale size and price range but no context on total insider holdings, other concurrent transactions, or whether the plan was modified.

Relevance 4/10Novelty 2/10Timing: Filed July 14 after July 13 insider sale.

Background

The article is an SEC Form 4 insider transaction for Liquidia Corp, reporting an open-market sale by the Chief Commercial Officer.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia CCO Moomaw Scott sold $682,141 of LQDA shares in two open-market trades under a 10b5-1 plan on July 13.

Expected impact

Likely limited near-term impact; any effect is more about signaling than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it does not include new company performance, guidance, or regulatory/clinical developments.

Market effects

No clear sector read-through; this is company-specific insider trading with no disclosed operational change.

None.

None.

Counterpoint

Insider selling can sometimes precede negative developments, but this transaction is explicitly under a 10b5-1 plan, reducing interpretive value.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure.

  • Moomaw Scott

    Chief Commercial Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.